Find trials
Consejos para buscar

Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome

Overview

Información sobre este estudio

This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associated with changes in symptom severity in IBS, and if targeted dietary interventions, including prebiotics, can reverse or moderate these changes.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

IBS-C and IBS-D SUBJECTS:

Inclusion Criteria:

  • Clinical diagnosis of IBS-C or IBS-D
  • Age 18 to 65

Exclusion Criteria:

  • Prior history of abdominal surgeries (except appendectomy and cholecystectomy)
  • Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory condition
  • Antibiotic use within the past 4 weeks (they can be enrolled after a four-week washout period and subsequent use during the 6-month study duration does not exclude them)
  • Bleeding risk or medications which may increase risk of bleeding for patients who agree to undergo flexible sigmoidoscopy
  • Bowel preparation for colonoscopy within the past week
  • Pregnancy or plans to become pregnant within the study time frame
  • Vulnerable adults
  • Age greater than or equal to 66
  • Any other disease(s), condition(s) or habit(s) that would interfere with completion of the study, would increase risks of flexible sigmoidoscopy (for those opting for this), or in the judgment of the investigator would potentially interfere compliance to this study or would adversely affect study outcomes

HEALTHY SUBJECTS:

Inclusion Criteria:

  • Age 18 to 65
  • No clinical diagnosis of IBS-C or IBS-D

Exclusion Criteria:

  • Prior history of abdominal surgeries (except appendectomy and cholecystectomy)
  • Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory condition
  • Antibiotic use within the past 4 weeks (they can be enrolled after a four-week washout period and subsequent use during the 6-month study duration does not exclude them)
  • Bleeding risk or medications which may increase risk of bleeding for patients who agree to undergo flexible sigmoidoscopy
  • Bowel preparation for colonoscopy within the past week
  • Pregnancy or plans to become pregnant within the study time frame
  • Vulnerable adults
  • Age greater than or equal to 66
  • Any other disease(s), condition(s) or habit(s) that would interfere with completion of the study, would increase risks of flexible sigmoidoscopy (for those opting for this), or in the judgment of the investigator would potentially interfere compliance to this study or would adversely affect study outcomes
  • Clinical diagnosis of IBS-C or IBS-D

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Purna Kashyap, M.B.B.S.

Cerrado para la inscripción

Contact information:

Heather Lekatz CCRP

(507) 538-1206

Lekatz.Heather@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20117986

Mayo Clinic Footer